By Ed SilvermanJune 8, 2026
Pharmalot Columnist, Senior Writer
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation. Our choice today is laced with chocolate raspberry. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today, and of course, do keep in touch. …
Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients, but its next act — this time as a co-lead — was just revealed, STAT points out. Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat and Revolution’s daraxonrasib led to durable responses in the large majority of pancreatic cancer patients who received both medicines. Tango’s strategy of testing the two targeted drugs is notable because combination approaches in pancreatic cancer often include chemotherapy. The recent successful Revolution trial that has upended the specialty tested daraxonrasib versus chemotherapy as a second-line treatment.
